Get the Stockscreener App
93.48
1.07%
0.99
After Hours:
93.48
Mirum Pharmaceuticals Inc stock is traded at $93.48, with a volume of 585.27K.
It is up +1.07% in the last 24 hours and down -11.65% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$92.49
Open:
$92.42
24h Volume:
585.27K
Relative Volume:
0.60
Market Cap:
$5.70B
Revenue:
$521.31M
Net Income/Loss:
$-23.36M
P/E Ratio:
-195.52
EPS:
-0.4781
Net Cash Flow:
$54.87M
1W Performance:
-7.90%
1M Performance:
-11.65%
6M Performance:
+36.51%
1Y Performance:
+109.36%
1-Day Range:
$91.89
$94.05
1-Week Range:
$90.59
$100.27
52-Week Range:
$45.17
$114.99
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
93.48 | 5.64B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Pharmaceuticals, Inc. Balance Sheet – XETR:08D - TradingView
EBITDA of Mirum Pharmaceuticals, Inc. – XETR:08D - TradingView
Discipline and Rules-Based Execution in MIRM Response - Stock Traders Daily
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report? - Yahoo Finance
Earnings call transcript: Mirum Pharmaceuticals Q1 2026 results reveal strong revenue growth - Investing.com
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - BioSpace
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com Canada
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress - Insider Monkey
Mirum Pharmaceuticals Insider Sold Shares Worth $2,875,103, According to a Recent SEC Filing - Moomoo
HC Wainwright & Co. Maintains Mirum Pharmaceuticals (MIRM) Buy Recommendation - MSN
Mirum director Saira Ramasastry sells $397,700 of company stock By Investing.com - Investing.com South Africa
Insider Sell: Saira Ramasastry Sells 3,977 Shares of Mirum Pharm - GuruFocus
Mirum CEO Peetz sells $2.88m in stock after exercising options - Investing.com Nigeria
Mirum director Saira Ramasastry sells $397,700 of company stock - Investing.com
Mirum CEO Peetz sells $2.88m in stock after exercising options By Investing.com - Investing.com India
Mirum (MIRM) director converts 3,977 restricted stock units into common shares - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO logs option exercise and 30K-share sale - Stock Titan
Mirum Pharmaceuticals (MIRM) director converts 3,977 RSUs into 9,680-share holding - Stock Titan
Mirum Pharmaceuticals (MIRM) director sells 3,977 shares under 10b5-1 plan - Stock Titan
MIRM Initiated Coverage by Citigroup -- Rating Set to Buy - GuruFocus
Insider sale and option exercise — MIRM: 40,985 shares sold, 30,000 planned - Stock Titan
3,977-share planned restricted-stock sale by MIRM (NASDAQ: MIRM) - Stock Titan
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline - Investing.com
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 - Weekly Voice
Mirum Pharma: A Rare Disease Growth Story to Watch - MarketBeat
Mirum Pharmaceuticals enters catalyst-rich stretch as LIVMARLI sales and pipeline advance - MSN
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 - MSN
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
US604749AC5 Latest News and Headlines - TradingView
Mirum Pharma: A rare disease growth story to watch - MSN
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance - Barchart.com
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
US604749AC5 Bond Analysis — Key Metrics - TradingView
US604749AC5 Bond Price and Chart — FWB:US604749AC5 - TradingView
Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM) - Yahoo Finance
Behavioral Patterns of MIRM and Institutional Flows - Stock Traders Daily
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - The Chronicle-Journal
Mirum Pharmaceuticals Set to Present Key Data at International L - GuruFocus
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 - Business Wire
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes - TipRanks
MIRM: Clinical and commercial catalysts drive growth, with major pipeline and BD milestones ahead - TradingView
Wolfe Research initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mirum Pharmaceuticals Inc Stock (MIRM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jun 01 '26 |
Sale |
95.84 |
30,000 |
2,875,103 |
194,309 |
| Ramasastry Saira | Director |
Jun 01 '26 |
Sale |
100.00 |
3,977 |
397,700 |
0 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):